COVID-19 UPDATE

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.
February 26, 2021

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19. These are great news, as now there are a total of 5 products being evaluated by EMA (3 vaccines and 2 treatments) which could be placed on the market during the following months, depending on the results of the evaluation.

The development of new tools to treat COVID-19 brings renewed hopes to fight against the pandemic. At Asphalion we are actively aiding in the development of vaccines and treatments for COVID-19, bringing our best to help all developers get their products ready to be authorized.

For further information you can contact us at: [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting